InnoGen Pharmaceuticals
Concise Prescribing Info
Biperiden HCl
Symptomatic treatment of parkinsonism including the alleviation of extrapyramidal syndrome induced by drugs eg, phenothiazines.
Dosage/Direction for Use
Parkinsonism Initially 2 mg tid-qid. Max dose: 16 mg daily. Drug-induced extrapyramidal symptoms 2 mg once daily to tid.
Should be taken with food.
Hypersensitivity. Narrow angle glaucoma, bowel obstruction, megacolon.
Special Precautions
Cases of mental confusion, euphoria, agitation & disturbed behavior. Risk of central anticholinergic syndrome. Patients w/ glaucoma, prostatism, epilepsy, cardiac arrhythmia, heart failure, cardiac surgery, acute MI & HTN. Do not give in patients w/ angle-closure glaucoma or w/ narrow angle between iris & cornea. May raise IOP & precipitate acute attack. Caution in conditions characterised by tachycardia eg, thyrotoxicosis, heart failure & in cardiac surgery, where they may further accelerate heart rate. Reduced bronchial secretion. Avoid abrupt w/drawal. May impair ability to drive or operate machinery. Childn. Elderly.
Adverse Reactions
Dry mouth w/ difficulty in swallowing & talking, thirst, reduced bronchial secretions, mydriasis, cycloplegia & photophobia, flushing & dryness of the skin, transient bradycardia followed by tachycardia w/ palpitation & arrhythmias; difficulty in micturition, reduction in the tone & motility of the GIT leading to constipation.
Drug Interactions
Enhanced effects w/ drugs w/ antimuscarinic properties eg, amantadine, some antihistamines, phenothiazine antipsychotics, TCAs, MAOIs. May antagonise GI effects of cisapride, domperidone & metoclopramide. May counteract the effects of parasympathomimetics.
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04AA02 - biperiden ; Belongs to the class of tertiary amines anticholinergic agents. Used in the management of Parkinson's disease.
BiZyx tab 2 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in